The Potential of Non-Dissociative Ketamine with Hans Eriksson MD, PhD, MBA

The Potential of Non-Dissociative Ketamine with Hans Eriksson MD, PhD, MBA

Author: Lynn Marie Morski, MD, JD May 22, 2024 Duration: 31:20
Psychedelic Medicine Podcast with Dr. Lynn Marie Morski
HealthHealth & FitnessFitnessMedicineMental

In this episode of the Psychedelic Medicine Podcast, Dr. Hans Eriksson joins to discuss the potential of non-dissociative ketamine. Dr. Eriksson, Chief Medical Officer at HMNC Brain Health, is a highly respected drug developer and clinical psychiatrist with over 20 years of pharmaceutical experience. Prior to HMNC Brain Health, Dr. Eriksson served as Chief Medical Officer at COMPASS Pathways and previously as Senior Director of Clinical Research at Lundbeck and Medical Science Director at AstraZeneca.

In this conversation, Dr. Eriksson shares what inspired him to move from clinical practice to drug development, and why he sees so much potential in developing non-dissociative forms of ketamine. He discusses the ways the dissociative effects of ketamine decrease the accessibility of this treatment due to the fact that these changes in perception are undesirable for a significant portion of patients. Dr. Eriksson also shares results from preliminary studies of non-dissociative ketamine which showed efficacy in inducing anti-depressant effects. In closing, Dr. Eriksson discusses why he thinks the experiential element of the classical psychedelics play an important role in their efficacy as mental health treatments, but why this might not be the case when it comes to ketamine. 

 

In this episode you'll hear:

  • The history of ketamine
  • The pharmacology of ketamine's dissociative effect
  • The relationship between ketamine dose and antidepressant effect 
  • The possibility of bladder issues and addiction with ketamine and whether non-dissociative forms of ketamine would also have these potentials
  • How Dr. Eriksson thinks about combining psychotherapy with ketamine treatments

 

Quotes:

"We are aiming for a similar exposure to the drug as you achieve with, for instance, an intravenous administration, but we are achieving a much lower peak concentration, maximum concentration of the compound. So that is one of the characteristics of our formulation." [10:58]

"Our view is that it's probably better to try to use the metabolism in the body as a tool to achieve very low exposure to ketamine but high exposure to the downstream metabolites." [23:19]

 

Links:

Dr. Eriksson on LinkedIn

HMNC Brain Health on LinkedIn

HMNC Brain Health website

Previous episode: Potential Benefits of Non-Hallucinogenic Psychedelics with Kurt Rasmussen, PhD

Psychedelic Medicine Association

Porangui


Exploring the frontier of mind and medicine, the Psychedelic Medicine Podcast with Dr. Lynn Marie Morski delves into the complex world of psychedelic substances and their potential to heal. Hosted by Lynn Marie Morski, a physician and attorney, this podcast navigates the intricate intersection of cutting-edge science, clinical practice, and evolving policy. Each episode brings a grounded, expert perspective to conversations about psilocybin, MDMA, ketamine, LSD, ayahuasca, ibogaine, and other compounds, moving beyond hype to examine the real-world implications of this therapeutic renaissance. Listeners will hear detailed discussions on the latest peer-reviewed research, practical insights from medical professionals integrating these approaches, and thoughtful analysis of the legal landscape shaping access. The dialogue is rooted in a commitment to safety, ethics, and evidence, offering a clear-eyed look at both the profound promise and the challenges inherent in psychedelic medicine. Whether you're a healthcare provider, a patient, a researcher, or simply intellectually curious, this podcast provides an essential, nuanced resource for understanding how these ancient and modern substances are reshaping perspectives on mental health, consciousness, and treatment. It’s a space for serious inquiry, where complex questions about healing, neuroscience, and society are met with informed, accessible conversation.
Author: Language: English Episodes: 100

Official website RSS
instagramlinkedin
Psychedelic Medicine Podcast with Dr. Lynn Marie Morski
Podcast Episodes
Ayahuasca for PTSD with Dr. Simon Ruffell MBChB, MRCPsych, PhD [not-audio_url] [/not-audio_url]

Duration: 47:29
In this episode Dr. Simon Ruffell joins to discuss the research on ayahuasca for PTSD. Dr. Ruffell is a psychiatrist, researcher, and student of curanderismo (Amazonian shamanism) working at the intersection of Western p…
Psychedelics and Religion with Hunt Priest, MDiv [not-audio_url] [/not-audio_url]

Duration: 45:51
In this episode, Hunt Priest joins to discuss the intersection of psychedelic experiences and religion. Hunt is the founder of Ligare: A Christian Psychedelic Society and was a participant in the Johns Hopkins/NYU Psiloc…
Which Psychedelic for Which Condition? with Will Van Derveer, MD [not-audio_url] [/not-audio_url]

Duration: 45:08
In this episode, Will Van Derveer, MD joins to unpack what we know about which psychedelic medicines are best suited to particular mental health conditions. Dr. Van Derveer has trained several thousand mental health prof…
Psychedelics for the Menopause Transition with Alicia Bigelow, ND [not-audio_url] [/not-audio_url]

Duration: 35:26
In this episode, Alicia Bigelow, ND joins to discuss the potential of psychedelic medicine to support the menopause transition. Dr. Ali Bigelow is a naturopathic physician, ketamine provider and licensed psilocybin facil…
Psychedelics and Movement with Dmitry Repin, PhD [not-audio_url] [/not-audio_url]

Duration: 30:24
In this episode, Dmitry Repin, PhD joins to discuss the intersection of bodily movement and psychedelics. Dr. Repin is the co-founder of the Institute for Psychedelic Research at Tel Aviv University, holds a PhD in cogni…

12345...10»